The FDA has granted approval for the Wegovy pill, developed by Novo Nordisk, marking the launch of the first oral GLP-1 medication for weight loss. This new formulation, a daily pill version of the previously injectable drug, represents a significant advancement in obesity treatment. Following the announcement, shares of Novo Nordisk surged by approximately 7%, reflecting strong investor confidence in the potential demand for this easier-to-use option. The approval positions Novo Nordisk at the forefront of the growing market for oral weight-loss medications.